Zoetis (ZTS)
(Delayed Data from NYSE)
$144.09 USD
-0.01 (-0.01%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $144.08 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Zoetis Inc. has a PEG ratio of 2.36 compared to the Medical - Drugs industry's PEG ratio of 1.17.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZTS 144.09 -0.01(-0.01%)
Will ZTS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ZTS based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ZTS
Seeking Clues to Zoetis (ZTS) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
Zoetis (ZTS) Ascends But Remains Behind Market: Some Facts to Note
Other News for ZTS
Top 15 High-Growth Dividend Stocks For November 2025
ZTS Crossed Above 20 Day Moving Average on October 31
ZTS forms 20 Day Moving Average Resistance on October 30
Stifel Nicolaus Keeps Their Hold Rating on Zoetis (ZTS)
Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q3 2025 Update